The number of patients living with end-stage heart failure is steadily growing. Although
originally intended to serve solely as a bridge to more definitive surgical therapies,
there is an increasing number of patients receiving inotropic therapy (milrinone,
dobutamine) for purely palliative purposes. Continuous infusion may increase quality
of life and reduce symptom burden at the cost of increasing mortality.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the American Medical Directors AssociationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
